|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
The global emergence of multidrug-resistant organisms poses an existential threat to individual patients and society at large. In order to meet the challenge presented by this dynamic landscape, pharmacists must understand the epidemiology and nuanced resistance mechanisms involved, as well as cutting-edge treatment and prevention strategies. This 1.5-hour webinar activity provides valuable insights from expert faculty regarding the epidemiology and pharmacotherapeutic management of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum beta-lactamases (ESBLs), carbapenem-resistant Enterobacterales (CRE), multidrug-resistant Pseudomonas, and carbapenem-resistant Acinetobacter baumannii (CRAB). This activity is intended for pharmacists, including board-certified infectious diseases pharmacists (BCIDPs), who are seeking to update their knowledge base and explore contemporary treatment strategies for these difficult-to-treat infections.
The target audience for this activity includes pharmacists and board-certified infectious diseases pharmacists (BCIDPs). At the completion of this activity, the participant will be able to:
- Discuss the prevalence and epidemiology of multidrug resistant bacteria.
- Discuss the mechanisms of resistance for common multidrug resistant (MDR) pathogens.
- Describe the microbiology challenges associated with the identification of multidrug-resistant bacteria.
- Describe the current evidence-based treatment options for management of invasive multidrug resistant bacteria and review changes in the CLSI breakpoints.
David Burgess, Pharm.D., FCCP, FIDP
Professor and Chair, Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Release Date: July 8, 2021
Expiration Date: July 8, 2022
This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-296-H01-P has been assigned to this home-study, knowledge-based activity. This activity is approved for 1.5 contact hour (0.15 CEU) in states that recognize ACPE providers. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 07/8/2021 for this activity and is available for one year from this date.
Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), the American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. David Burgess has no conflict of interest to report.
This activity is provided by ProCE, LLC and SIDP.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
LIVE Webinar Attendance (Enter Event/Attendance Code provided during webinar to verify attendance)
|Date||7/8/2021 9:00:00 AM|